Humacyte, Inc. (NASDAQ:HUMA - Get Free Report)'s stock price was down 5.8% on Monday . The company traded as low as $5.12 and last traded at $5.18. Approximately 3,711,508 shares were traded during mid-day trading, an increase of 31% from the average daily volume of 2,841,564 shares. The stock had previously closed at $5.50.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on HUMA. Cantor Fitzgerald reissued an "overweight" rating and set a $13.00 price target on shares of Humacyte in a research report on Friday, September 20th. Piper Sandler set a $6.00 target price on shares of Humacyte and gave the company a "neutral" rating in a report on Friday, October 18th. BTIG Research reissued a "buy" rating and issued a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price objective on shares of Humacyte in a research report on Friday, December 20th. Finally, HC Wainwright reissued a "buy" rating and issued a $15.00 target price (up from $12.00) on shares of Humacyte in a report on Friday, December 20th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Humacyte currently has an average rating of "Buy" and a consensus price target of $13.71.
View Our Latest Analysis on Humacyte
Humacyte Price Performance
The firm has a fifty day moving average of $4.77 and a 200 day moving average of $5.73. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.61. The company has a market capitalization of $640.62 million, a P/E ratio of -3.80 and a beta of 1.38.
Insider Transactions at Humacyte
In other news, Director Brady W. Dougan sold 427,459 shares of the firm's stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total value of $1,855,172.06. Following the transaction, the director now directly owns 1,992,253 shares in the company, valued at $8,646,378.02. This trade represents a 17.67 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Laura E. Niklason sold 261,369 shares of the company's stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total value of $1,150,023.60. Following the sale, the chief executive officer now owns 1,730,884 shares of the company's stock, valued at approximately $7,615,889.60. This trade represents a 13.12 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,500,000 shares of company stock worth $6,606,799 over the last three months. 11.20% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Humacyte
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Barclays PLC increased its holdings in Humacyte by 177.6% during the third quarter. Barclays PLC now owns 236,742 shares of the company's stock valued at $1,288,000 after buying an additional 151,458 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Humacyte by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 2,040,218 shares of the company's stock worth $11,101,000 after purchasing an additional 179,120 shares in the last quarter. XTX Topco Ltd increased its stake in shares of Humacyte by 48.8% in the 3rd quarter. XTX Topco Ltd now owns 34,049 shares of the company's stock worth $185,000 after purchasing an additional 11,172 shares in the last quarter. Insigneo Advisory Services LLC bought a new position in Humacyte in the 3rd quarter worth $109,000. Finally, Wellington Management Group LLP lifted its position in Humacyte by 30.9% during the third quarter. Wellington Management Group LLP now owns 254,411 shares of the company's stock valued at $1,384,000 after purchasing an additional 60,087 shares in the last quarter. Hedge funds and other institutional investors own 44.71% of the company's stock.
Humacyte Company Profile
(
Get Free Report)
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Further Reading
Before you consider Humacyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.
While Humacyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
